Tuesday, 26 April 2011

Update: Partial Clinical Hold Lifted by FDA for GSK2402968 (Exon 51 Skip)

Update: Partial Clinical Hold Lifted by FDA for GSK2402968 (Exon 51 Skip): "GlaxoSmithKline (GSK) has provided an update regarding the clinical development program for GSK2402968 (exon 51 skip) for DMD: The US Food and Drug Administration has lifted the partial clinical hold on the Investigational New Drug Application for GSK2402968. This means GSK can now proceed with longer term clinical studies of GSK2402968 in DMD patients in the US."

No comments:

Post a comment